Luminex (NASDAQ: LMNX) and Hansen Medical (NASDAQ:HNSN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.
This table compares Luminex and Hansen Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Luminex and Hansen Medical’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Luminex||$270.64 million||3.34||$13.81 million||$0.66||31.11|
Luminex has higher revenue and earnings than Hansen Medical. Hansen Medical is trading at a lower price-to-earnings ratio than Luminex, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and recommmendations for Luminex and Hansen Medical, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Luminex presently has a consensus target price of $19.33, suggesting a potential downside of 5.83%. Given Luminex’s higher probable upside, equities analysts clearly believe Luminex is more favorable than Hansen Medical.
Insider & Institutional Ownership
79.2% of Luminex shares are owned by institutional investors. 6.9% of Luminex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Luminex pays an annual dividend of $0.24 per share and has a dividend yield of 1.2%. Hansen Medical does not pay a dividend. Luminex pays out 36.4% of its earnings in the form of a dividend.
Luminex beats Hansen Medical on 9 of the 10 factors compared between the two stocks.
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The Company has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to a range of testing laboratories.
About Hansen Medical
Hansen Medical, Inc. is engaged in the development and marketing of medical devices. The Company develops, manufactures and sells a range of medical robotics designed for positioning, manipulation and stable control of catheters and catheter-based technologies. Its products include Sensei Robotic Catheter System (Sensei system), Artisan Extend Control Catheter, CoHesion 3D Visualization Module and Magellan System. Its Sensei system allows physicians to navigate catheters in interventional procedures within the atrial heart chambers. Its disposable Artisan Extend catheter assembly consists of a telescoping set of control catheters. Its CoHesion 3D Visualization Module is a software interface between its Sensei system and the St. Jude Medical EnSite System for Electro-Physiology procedures. The Magellan System controls the Magellan Robotic Catheter, which is a telescoping, steerable catheter designed to facilitate remote catheter navigation and vessel cannulation.
What are top analysts saying about Luminex? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Luminex and related companies.